GlassScriptPhysician profile
Sudheer Gurram
NPI 1336201243
$3,203.35
in general payments reported to CMS, 2019-2025
38 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $259 · 2021: $727 · 2022: $626 · 2023: $306 · 2024: $443 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $439.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $435.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $307.06 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $290.87 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $190.43 | 2022-2025 | |
| Travere Therapeutics, INC. | $124.99 | 2023 | |
| Janssen Pharmaceuticals, INC | $122.02 | 2019-2020 | |
| Pfizer INC. | $116.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.20 | 2021-2024 | Xifaxan, Trulance |
| Abbvie INC. | $81.45 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.32 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $63.06 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $59.72 | 2019-2022 | |
| Novo Nordisk INC | $57.53 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $57.15 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $56.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $50.51 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $45.76 | 2020-2021 | |
| Lilly USA, LLC | $42.83 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Lundbeck LLC | $41.84 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.49 | 2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $36.62 | 2021-2022 | |
| Astellas Pharma US INC | $32.55 | 2020-2021 | |
| Galderma Laboratories, L.P. | $27.22 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $27.19 | 2019-2021 | |
| Daiichi Sankyo INC. | $23.19 | 2021 | |
| Acadia Pharmaceuticals INC | $22.61 | 2022 | |
| Covis Pharma Gmbh | $18.90 | 2022 | |
| Alkermes, INC. | $18.11 | 2025 | Lybalvi |
| Cmp Pharma, INC. | $16.72 | 2022 | |
| Alfasigma USA, INC. | $16.50 | 2021 | |
| Eisai INC. | $16.37 | 2021 | |
| Genzyme Corporation | $15.41 | 2022 | |
| Boston Scientific Corporation | $15.00 | 2022 | |
| Exact Sciences Corporation | $14.45 | 2025 | Cologuard Collection Kit |
| Nevro Corp. | $13.30 | 2022 | |
| Kaleo, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudheer Gurram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.